| Returns | 1W : -3.6% , 1M : 5%,1Y : 420.6% |
| Peers & Returns | 1W | 1M | 1Y |
| GUJARAT THEMIS BIOSYN LTD | -3.6% | 5% | 420.6% |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 1.7% | 10.4% | 10.3% |
| DR REDDYS LABORATORIES LTD | 4.9% | -1% | 61.7% |
| DIVIS LABORATORIES LTD | 2.2% | 13.1% | 91.7% |
| CIPLA LTD | -0.3% | -3.5% | 56.4% |
| BIOCON LTD | 1.4% | 4.8% | 51.9% |
| AUROBINDO PHARMA LTD | 4.5% | 12.2% | 88.1% |
| LUPIN LTD | 2.4% | -4.4% | 12.9% |
| TORRENT PHARMACEUTICALS LTD | 0.3% | 2.8% | 37.8% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S |
15.65
P/E Calculated based on EPS of 16.3
[ Mar2020 - Standalone Results ] 8.78
P/B Calculated based on Book Value of 29.04
[ Mar2020 - Standalone Results ] 4.15
P/S Calculated based on Revenues of 89.079 Cr
[ TTM - Standalone Results ] |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
NA 420% 433% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2020 2019 2018 Avg_3yrs |
0.19 0.32 0.05 0.19 |
- - - - |
|
[Last Annual Data : Mar2020]
|
||
| Pledged Shares |
0 % |
|---|---|
| As on : Sep2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Standalone | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
73.64% 110.67% 119.14% 103.61% |
65.19% 526.3% 663.42% 607.74% |
| QtrlyTrend |
8
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Sep2020 | ||
